Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
CONCLUSIONS: This study indicates that a single dose of palifermin used as primary prophylaxis during HSTC therapy can prevent severe OM in pediatric patients with ALL and used as secondary prophylaxis can prevent the recurrence of severe OM in high-risk patients with previous mucosal injury and improves the quality of life in pediatric patients with ALL.
PMID: 26862696 [PubMed - as supplied by publisher]
Source: Minerva Stomatologica - Category: Dentistry Tags: Minerva Stomatol Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Clinical Trials | Dentistry | Leukemia | Pediatrics | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants